ORASURE TECHNOLOGIES, INC (OSUR) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 25.12M USD | Liabilities, Current |
| Cash and equivalents | 160.58M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | 25.60M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 30.07M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $25.12M | $160.58M | (m) | $25.60M | $30.07M | (m) |
| 2026-03-31 | (m) | $44.08M | $176.96M | (m) | $24.81M | $30.31M | (m) |
| 2025-12-31 | (m) | $39.80M | $199.28M | (m) | $22.20M | $31.06M | (m) |
| 2025-09-30 | (m) | $40.25M | $216.48M | (m) | $24.30M | $33.40M | (m) |
| 2025-06-30 | (m) | $42.35M | $234.58M | (m) | $25.90M | $33.38M | (m) |
| 2025-03-31 | (m) | $25.42M | $247.57M | (m) | $21.52M | $35.68M | (m) |
| 2024-12-31 | (m) | $33.48M | $267.76M | (m) | $23.82M | $34.20M | (m) |
| 2024-09-30 | (m) | $27.78M | $278.57M | (m) | $26.95M | $38.87M | (m) |
| 2024-06-30 | $305.48M | $28.85M | $258.24M | $9.14M | $38.10M | $38.26M | 10.59× |
| 2024-03-31 | $297.81M | $29.11M | $247.15M | $16.63M | $34.04M | $43.18M | 10.23× |
| 2023-12-31 | (m) | $39.54M | $290.41M | (m) | $40.17M | $47.61M | (m) |
| 2023-09-30 | $278.29M | $40.95M | $217.53M | $7.36M | $53.40M | $59.26M | 6.80× |
| 2023-06-30 | (m) | $46.42M | $185.94M | (m) | $52.75M | $73.28M | (m) |
| 2023-03-31 | (m) | $55.12M | $90.19M | (m) | $107.44M | $77.19M | (m) |
| 2022-12-31 | (m) | $70.39M | $83.98M | (m) | $70.80M | $96.23M | (m) |
| 2022-09-30 | (m) | $71.70M | $75.20M | (m) | $61.31M | $78.81M | (m) |
| 2022-06-30 | (m) | $65.49M | $66.16M | (m) | $62.89M | $71.30M | (m) |
| 2022-03-31 | (m) | $55.59M | $70.72M | (m) | $59.67M | $61.54M | (m) |
| 2021-12-31 | (m) | $68.06M | $116.76M | (m) | $45.32M | $53.14M | (m) |
| 2021-09-30 | (m) | $54.17M | $134.96M | (m) | $40.08M | $53.58M | (m) |
| 2021-06-30 | (m) | $46.57M | $158.12M | (m) | $35.26M | $48.17M | (m) |
| 2021-03-31 | (m) | $44.64M | $177.68M | (m) | $36.39M | $40.35M | (m) |
| 2020-12-31 | (m) | $46.49M | $160.80M | (m) | $38.84M | $31.86M | (m) |
| 2020-09-30 | (m) | $37.23M | $162.86M | (m) | $30.64M | $30.49M | (m) |
| 2020-06-30 | (m) | $30.59M | $173.87M | (m) | $25.92M | $27.71M | (m) |
| 2020-03-31 | (m) | $26.34M | $83.36M | (m) | $27.86M | $22.69M | (m) |
| 2019-12-31 | (m) | $32.71M | $75.72M | (m) | $36.95M | $23.16M | (m) |
| 2019-09-30 | (m) | $28.94M | $85.47M | (m) | $27.76M | $25.04M | (m) |
| 2019-06-30 | (m) | $29.95M | $72.57M | (m) | $29.39M | $25.67M | (m) |
| 2019-03-31 | (m) | $27.31M | $69.52M | (m) | $24.91M | $26.21M | (m) |
| 2018-12-31 | (m) | $27.98M | $88.44M | (m) | $34.84M | $22.89M | (m) |
| 2018-09-30 | (m) | $21.42M | $78.15M | (m) | $33.28M | $19.90M | (m) |
| 2018-06-30 | (m) | $21.12M | $71.05M | (m) | $31.65M | $20.60M | (m) |
| 2018-03-31 | (m) | $21.19M | $64.04M | (m) | $28.20M | $20.91M | (m) |
| 2017-12-31 | (m) | $32.24M | $71.03M | (m) | $42.52M | $19.34M | (m) |
| 2017-09-30 | (m) | $26.62M | $76.77M | (m) | $28.10M | $16.86M | (m) |
| 2017-06-30 | (m) | $23.19M | $104.87M | (m) | $26.73M | $14.55M | (m) |
| 2017-03-31 | (m) | $18.28M | $120.85M | (m) | $24.00M | $12.71M | (m) |
| 2016-12-31 | (m) | $17.34M | $107.96M | (m) | $19.83M | $11.80M | (m) |
| 2016-09-30 | (m) | $21.95M | $111.73M | (m) | $15.47M | $12.07M | (m) |
| 2016-06-30 | (m) | $26.07M | $105.70M | (m) | $18.44M | $11.37M | (m) |
| 2016-03-31 | (m) | $20.34M | $94.56M | (m) | $16.73M | $12.32M | (m) |
| 2015-12-31 | (m) | $25.23M | $94.09M | (m) | $19.27M | $13.24M | (m) |
| 2015-09-30 | (m) | $29.70M | $100.68M | (m) | $17.09M | $14.98M | (m) |
| 2015-06-30 | (m) | $15.60M | $83.40M | (m) | $16.36M | $15.65M | (m) |
| 2015-03-31 | (m) | $17.53M | $85.55M | (m) | $16.37M | $15.62M | (m) |
| 2014-12-31 | (m) | $26.46M | $92.87M | (m) | $16.14M | $15.76M | (m) |
| 2014-09-30 | (m) | $25.25M | $93.86M | (m) | $14.92M | $14.84M | (m) |
| 2014-06-30 | (m) | $14.71M | $75.83M | (m) | $14.15M | $13.23M | (m) |
| 2014-03-31 | (m) | $14.97M | $84.19M | (m) | $13.29M | $11.99M | (m) |
| 2013-12-31 | (m) | $18.98M | $93.19M | (m) | $12.96M | $11.44M | (m) |
| 2013-09-30 | (m) | $19.33M | $82.59M | (m) | $14.29M | $12.00M | (m) |
| 2013-06-30 | (m) | $15.98M | $76.96M | (m) | $15.36M | $12.50M | (m) |
| 2013-03-31 | (m) | $17.99M | $79.28M | (m) | $16.95M | $13.06M | (m) |
| 2013-01-01 | (m) | (m) | $87.89M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $16.92M | $87.89M | (m) | $17.55M | $12.76M | (m) |
| 2012-09-30 | (m) | $17.00M | $89.42M | (m) | $19.31M | $12.84M | (m) |
| 2012-06-30 | (m) | $20.80M | $23.27M | (m) | $15.41M | $11.02M | (m) |
| 2012-03-31 | (m) | $19.13M | $22.81M | (m) | $13.29M | $10.82M | (m) |
| 2011-12-31 | (m) | $21.98M | $23.88M | (m) | $17.16M | $9.62M | (m) |
| 2011-09-30 | (m) | $20.30M | $21.37M | (m) | $14.36M | $9.45M | (m) |
| 2011-06-30 | (m) | $20.05M | $75.40M | (m) | $11.74M | $8.15M | (m) |
| 2011-03-31 | (m) | (m) | $70.54M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $19.68M | $73.84M | (m) | $12.47M | $7.35M | (m) |
| 2010-09-30 | (m) | (m) | $71.70M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $72.55M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $74.93M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $39.57M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |